Supplementary Figure 2 from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 106KB, Schematic representation of the study design. 37 IMT tumor samples from 33 patients were collected under IRB approved protocols. ALK immunohistochemistry (IHC) was performed on each of the 37 cases as standard of clinical care. Targeted next-generation sequencing (NGS) using the FoundationOne was completed in each case. 22/26 ALK IHC+ and 11/11 ALK IHC- samples were evaluable. ALK kinase fusions were detected in 20/22 (91%) of the ALK IHC+ cases. In the ALK IHC- cases, 2/11 (18%) harbored ALK fusions, 2/11 (18%) harbored PDGFRβ fusions, and 4/11 (36%) harbored ROS1 fusions. Overall, therapeutically actionable kinase fusions were detected in 28/33 (85%) of cases.
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362482575